Early detection rate changes from a brain-responsive neurostimulation system predict efficacy of newly added antiseizure drugs.

ABSTRACT:

Objective

Brain-responsive neurostimulation (RNS System, NeuroPace) is used to treat medically refractory focal epilepsy and also provides long-term ambulatory neurophysiologic data. We sought to determine whether these data could predict the clinical response to antiseizure drugs (ASDs).

Methods

First, newly added medications were identified in RNS System patients followed at a single epilepsy center. Daily detection rates including "episode starts" (predominantly interictal activity) and "long episodes" (often electrographic seizures) were compared before and after ASD initiation. Efficacy was determined from documentation of clinical improvement and medication retention. Next, the analysis was repeated on an independent sample of patients from a multicenter long-term trea

SUBMITTER: Quraishi IH 

PROVIDER: S-EPMC7003822 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature